首页> 外文期刊>Diabetes >PXR Ablation Alleviates Diet-Induced and Genetic Obesity and Insulin Resistance in Mice
【24h】

PXR Ablation Alleviates Diet-Induced and Genetic Obesity and Insulin Resistance in Mice

机译:PXR消融减轻了小鼠的饮食诱发和遗传性肥胖以及胰岛素抵抗

获取原文
获取原文并翻译 | 示例
       

摘要

The pregnane X receptor (PXR), along with its sister receptor constitutive androstane receptor (CAR), was initially characterized as a xenobiotic receptor that regulates drug metabolism. In this study, we have uncovered an unexpected endobiotic role of PXR in obesity and type 2 diabetes. PXR ablation inhibited high-fat diet (HFD)-induced obesity, hepatic steatosis, and insulin resistance, which were accounted for by increased oxygen consumption, increased mitochondrial β-oxidation, inhibition of hepatic lipogenesis and inflammation, and sensitization of insulin signaling. In an independent model, introducing the PXR~(-/-) allele into the ob/ob background also improved body composition and relieved the diabetic phenotype. The ob/ob mice deficient of PXR showed increased oxygen consumption and energy expenditure, as well as inhibition of gluconeogenesis and increased rate of glucose disposal during euglycemic clamp. Mechanistically, the metabolic benefits of PXR ablation were associated with the inhibition of c-Jun NH_2-terminal kinase activation and downregula-tion of lipin-1, a novel PXR target gene. The metabolic benefit of PXR ablation was opposite to the reported prodiabetic effect of CAR ablation. Our results may help to establish PXR as a novel therapeutic target, and PXR antagonists may be used for the prevention and treatment of obesity and type 2 diabetes.
机译:孕烷X受体(PXR)及其姊妹受体组成型雄激素受体(CAR)最初被表征为调节药物代谢的异种受体。在这项研究中,我们发现了PXR在肥胖和2型糖尿病中的意外内生作用。 PXR消融抑制了高脂饮食(HFD)引起的肥胖症,肝脂肪变性和胰岛素抵抗,这是由于耗氧量增加,线粒体β-氧化增加,肝脂肪生成和炎症抑制以及胰岛素信号敏化引起的。在独立模型中,将PXR〜(-/-)等位基因引入ob / ob背景也可以改善人体成分,减轻糖尿病的表型。缺乏PXR的ob / ob小鼠在正常血糖钳制过程中显示出增加的耗氧量和能量消耗,以及抑制糖原异生和增加的葡萄糖处置率。从机理上讲,PXR消融的代谢益处与抑制c-Jun NH_2-末端激酶的活化和下调脂蛋白-1(一种新的PXR靶基因)有关。 PXR消融的代谢益处与CAR消融的报道的促糖尿病作用相反。我们的结果可能有助于将PXR确立为新型治疗靶标,并且PXR拮抗剂可用于预防和治疗肥胖症和2型糖尿病。

著录项

  • 来源
    《Diabetes》 |2013年第6期|1876-1887|共12页
  • 作者单位

    Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania,Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China;

    Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania;

    Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania;

    Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania;

    Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania;

    Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania;

    Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania,Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:25

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号